Shares of Gossamer Bio (GOSS) are on the rise on Monday after Aerovate Therapeutics (AVTE) said its AV-101 did not meet the primary endpoint in the company’s Phase 2b portion of its IMPAHCT study in patients with pulmonary arterial hypertension, or PAH. AV-101 has a… To see the rest of the story go to thefly.com. (See Story Here):(https://www.thefly.com/permalinks/entry.php/id3934429/-Gossamer-Bio-rises-following-competitors-failure-in-PAH-trial)
previous post
next post